0000899243-21-004516.txt : 20210202 0000899243-21-004516.hdr.sgml : 20210202 20210202210756 ACCESSION NUMBER: 0000899243-21-004516 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210201 FILED AS OF DATE: 20210202 DATE AS OF CHANGE: 20210202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TOMBESI PAOLO CENTRAL INDEX KEY: 0001707648 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35945 FILM NUMBER: 21583906 MAIL ADDRESS: STREET 1: 10 FINDERNE AVENUE STREET 2: BUILDING 10 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Epizyme, Inc. CENTRAL INDEX KEY: 0001571498 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261349956 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-229-5872 MAIL ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-01 0 0001571498 Epizyme, Inc. EPZM 0001707648 TOMBESI PAOLO C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 0 1 0 0 Chief Financial Officer Common Stock 2021-02-01 4 A 0 26041 0.00 A 54486 D Stock Option (Right to Buy) 11.02 2021-02-01 4 A 0 124239 0.00 A 2031-01-31 Common Stock 124239 124239 D Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in four equal annual installments over four years from the grant date, with the first installment vesting on February 1, 2022. The reporting person acquired 996 shares of Common Stock under the Issuer's 2013 Employee Stock Purchase Plan (the "2013 ESPP") on February 29, 2020 that were not previously reported on Form 4. The reporting person acquired 543 shares of Common Stock under the 2013 ESPP on August 31, 2020. This option was granted on February 1, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 124,239 shares of Common Stock, with 25% vesting on February 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. /s/ John Weidenbruch, attorney-in-fact 2021-02-02